# Supplemental Table 1. $\underline{\mathbf{A}}$ MEDLINE search strategy:

#	Search	Results
#1	"Peroxidase"[Mesh]	134863
#2	"Biomarkers" [Mesh]	800721
#3	"Inflammation Mediators"[Mesh]	361740
#4	#1 OR #2 OR #3	1137062
#5	"Myocardial Infarction" [Mesh]	161335
#6	"Acute Coronary Syndrome" [Mesh]	11907
#7	"Non-ST Elevated Myocardial Infarction" [Mesh]	211
#8	"Angina, Unstable"[Mesh]	10563
#9	#5 OR #6 OR #7 OR #8	175986
#10	"Prognosis"[Mesh]	1368644
#11	"Predictive Value of Tests"[Mesh])	175855
#12	#10 OR #11	1487900
#13	#4 And #9 And #12	3586

# Supplemental Table 1.B Scopus Search Strategy

<u>#</u>	Search terms	Results
	(ALL (peroxidase ) OR ALL (myeloperoxidase ) OR ALL (biomarkers ) AND (ALL (prognosis )) AND (ALL (myocardial AND infarction ) OR ALL (acute AND coronary AND syndrome ) OR ALL (non-st AND elevated AND myocardial AND infarction ) OR ALL (unstable AND angina ) AND NOT (ALL (cancer ) OR ALL (carcinoma ) OR ALL (aortic AND stenosis ) OR ALL (mice ) OR ALL (thyroid ) OR ALL (pancreas ) OR ALL (renal ) OR ALL (liver ) OR ALL (kidney ) OR ALL (leukemia ) OR ALL (tumor ) OR ALL (immunohistochemistry ) OR ALL (uterus ) OR (animals ) OR (prostate ) OR ALL (in AND vitro ) OR ALL (infection ) OR ALL (lymphoma ) OR ALL (epithelial AND cells ) OR ALL (lung ) OR ALL (gene ) OR ALL (genetic ) OR ALL (rabbit ) OR ALL (rats ) OR ALL (bone ) OR ALL (mineral ) OR (intestinal ) OR (intestine ) OR ALL (pulmonary ) OR ALL (environment ) OR ALL (brain ) OR ALL (sepsis ) OR ALL (psychosis ) OR ALL (colon ) OR ALL (case AND report ) OR (arthritis )) AND (LIMIT-TO (LANGUAGE , "English")) AND (LIMIT-TO (SUBJAREA . "MEDI" ))	904

# Supplemental Table 2. The definition of Major adverse cardiac events of the included studies in the meta-analysis.

Study	Major adverse cardiac events (MACE) definition
Apple <sup>20</sup>	A composite endpoint of the first recurrent MI, PCI, CABG, or cardiac death.
Brügger Andersen <sup>25</sup>	Recurrent TnT-positive ACS or cardiac death.
Chang <sup>26</sup>	A composite endpoint of advanced Killip score (defined as Killip classification ≥ 3) upon presentation, re-infarction, repeat PCI or mortality.
Eggers <sup>9</sup>	A composite endpoint of mortality and acute MI.
Kaya <sup>10</sup>	cardiac death; reinfarction; new hospital admission for angina; heart failure; and revascularization procedures by means of CABG or PCI.
Oemrawsingh <sup>23</sup>	A composite endpoint of all-cause mortality and non-fatal MI.

MI, Myocardial infraction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TnT, Cardiac troponin.

T; ACS, Acute coronary syndrome.

# Supplemental Table 3. Assessment the quality of the included studies using the Newcastle-Ottawa quality assessment scale:

Study	Selection				Comparabilit v	Ascertainment of outcome			Total Score
	Represe ntativen ess of the exposed cohort	Selection of the non- exposed cohort	Ascertain ment of exposure	Demonstrat ion that outcome of interest was not present at start of the study	Comparability of cohorts on the basis of the design or analysis	Independent assessment or record linkage	Follow up long enough for outcomes to occur	Adequac y of follow up of cohort	
	*	*	*	*	*	*	*	*	8
Apple [31]									
Baldus [34]	*	*	*	*	*	#	*	*	7
Brügger- Andersen [30]	*	*	*	*	**	*	*	*	9
Cavusoglu [38]	*	*	*	*	**	*	*	*	9
	*	*	*	*	*	#	\$	*	6
Chang [28]									

	*	*	*	*	*	*	*	*	8
Eggers [9]									
Kaya [10]	*	*	*	*	*	*	*	*	8
Koch [26]	*	*	*	*	**	#	*	*	8
Morrow [39]	*	*	*	*	*	*	*	*	8
Mocatta [40]	*	*	*	*	*	*	*	*	8
Oemrawsingh	*	*	*	*	**	*	*	*	9
[41]									
Rahman [32]	*	*	*	*		#	*	*	6
Scirica [29]	*	*	*	*	*	*	*	*	8

# No evidence of independent blind assessment of outcomes or linkage to patient's record, however we believe that the lack of blinding could have less likely introduced a risk of bias in evaluating our outcomes of interest. \$ follow up is 30 days. A maximum two stars can be given for comparability based on the number of risk factors they adjusted for.

#### **Supplemental Figure Legends:**

**Supplemental Figure 1.** Meta-regression for risk factors of Mortality. X axis represents the observed effect size of studies. Y is Meta-regression coefficient. Age (Y= - 0.12; P=0.32). Female (-8.61; P= 0.0048). ACS (Y=-0.071; P=0.94). DM (Y=3.522; P=0.32). Hypertension (Y-0.20; P=0.911). Smoking (Y=1.44; P=0.55).

**Supplemental Figure 2.** Meta-regression for risk factors of Major Adverse cardiac events. X axis represents the observed effect size of studies. Y is Meta-regression coefficient. Age (Y= - 0.112; P=0.28). Female (-3.15; P= 0.301). ACS (Y=-0.22; P=0.897). DM (Y= -0.353; P=0.89). Hypertension (Y-0.74; P=0.785). Smoking (Y=2.04; P=0.28).

Supplemental Figure 3. Meta-regression for risk factors of Recurrent Myocardial infraction.

X axis represents the observed effect size of studies. Y is Meta-regression coefficient. Age

(Y= - 0.03; P=0.68). Female (-2.23; P= 0.06). ACS (Y=-0.11; P=0.89). DM (Y= 2.0;

P=0.286). Hypertension (Y1.13; P=0.37). Smoking (Y=4.8; P=0.204).

**Supplemental Figure 4.** Forest Plot displays Sensitivity analysis using the one study removed method. High myeloperoxidase is significantly associated with mortality (odds ratio 2.040; 95% confidence interval [CI]: 1.405-2.960, p=0.000). High MPO showed a trend for developing major adverse cardiac events (odds ratio 1.421; 95% confidence interval [CI]: 1.010-1.999, p=0.044) and recurrent MI (odds ratio 1.241; 95% confidence interval [CI]: 0.996-1.545, p=0.054).

**Supplemental Figure 5.** Forest Plot displays Cumulative meta-analysis. High myeloperoxidase is significantly associated with mortality (odds ratio 2.040; 95% confidence interval [CI]: 1.405-2.960, p=0.000). High MPO showed a trend for developing major adverse

cardiac events (odds ratio 1.421; 95% confidence interval [CI]: 1.010-1.999, p=0.044) and recurrent MI (odds ratio 1.241; 95% confidence interval [CI]: 0.996-1.545, p=0.054).


**Supplemental Figure 6.** Funnel plot of all studies included in the meta-analysis. The Standard Error (SE) of the log Odds Ratio of each study was plotted against the Odds Ratio for mortality. No skewed distribution was observed, suggesting no publication bias.

**Supplemental Figure 7.** Funnel plot of all studies included in the meta-analysis. The Standard Error (SE) of the log Odds Ratio of each study was plotted against the Odds Ratio for major adverse cardiac events. No skewed distribution was observed, suggesting no publication bias.


**Supplemental Figure 8.** Funnel plot of all studies included in the meta-analysis. The Standard Error (SE) of the log Odds Ratio of each study was plotted against the Odds Ratio for recurrent myocardial infraction. No skewed distribution was observed, suggesting no publication bias.

# **Mortality**


### Regression of Log odds ratio on Age




### Regression of Log odds ratio on Female




# Regression of Log odds ratio on ACS




# Regression of Log odds ratio on DM



#### **Regression of Log odds ratio on HTN**




#### Regression of Log odds ratio on Smoking




# **Supplemental Figure 1.**

# Major adverse cardiac events


#### Regression of Log odds ratio on Age




#### Regression of Log odds ratio on Female




#### Regression of Log odds ratio on ACS




#### Regression of Log odds ratio on DM



#### Regression of Log odds ratio on HTN




## Regression of Log odds ratio on Smoking




# **Recurrent myocardial infarction**


#### Regression of Log odds ratio on Age




#### Regression of Log odds ratio on Female




#### Regression of Log odds ratio on ACS




#### Regression of Log odds ratio on DM




#### **Regression of Log odds ratio on HTN**




# Regression of Log odds ratio on Smoking





Favors low MPO Favors high MPO


**Supplemental Figure 4.** 



Favors low MPO Favors high MPO

**Supplemental Figure 5.** 


**Mortality**Funnel Plot of Standard Error by Log odds ratio



**Supplemental Figure 6.** 

### **Major adverse cardiac events**


Funnel Plot of Standard Error by Log odds ratio



Supplemental Figure 7.

### **Recurrent myocardial infarction**

Funnel Plot of Standard Error by Log odds ratio



Supplemental Figure 8.